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Multiparity decreases the risk of breast cancer in white women, whereas it is a risk factor in black women o50 years. Early-onset
breast cancer (o50 years) has been associated with high insulin-like growth factor-1 (IGF-1) levels. Absence of the common IGF1 19
cytosine-adenine (CA)-repeat allele (IGF1-19/-19) inverts the effect of several non-genetic factors on breast cancer risk but the
interaction between IGF1-19/-19 and multiparity on breast cancer risk is unknown. As IGF1-19/-19, multiparity and early-onset breast
cancer are more common in black than in white women, we aimed to study whether multiparity combined with IGF1-19/-19
increases the risk of early-onset breast cancer. Four hundred and three breast cancer patients diagnosed in Lund, Sweden, at age
25–99 years were genotyped for the IGF1 CA-repeat length using fragment analysis. Overall, 12.9% carried the IGF1-19/-19
genotype. There was a highly significant interaction between multiparity and IGF1-19/-19 on age at breast cancer diagnosis
(P¼0.007). Among IGF1-19/-19 patients, multiparity was associated with a 9.2 year earlier age at diagnosis compared with uniparity
or nulliparity (P¼0.006). Multiparity combined with IGF1-19/-19 was associated with an early age at breast cancer diagnosis. If
confirmed, IGF1-19/-19 may help identify a subgroup of women for earlier breast cancer screening.
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Breast cancer is the most common malignancy in women
worldwide (Parkin et al, 2001, 2002). Approximately 10% of
women living in Sweden will develop the disease during their
lifetime. The median age at breast cancer diagnosis in women in
Sweden is 60 years; approximately 4% of women are 40 years or
younger at diagnosis (data from the Swedish Cancer Registry). The
prognosis is often poorer in younger than in older women (Sidoni
et al, 2003) in terms of overall survival and relapse (Han et al,
2004), partly because young women do not benefit from breast
cancer screening and early-onset breast cancers are usually
detected clinically at a more advanced stage. In Lund, Sweden,
mammography screening is initiated at age 45 years and is
performed every 18 months until the age of 74 years. As of today,
no tests are routinely performed to identify the subgroup of
women who do not belong to high-risk breast cancer families (eg
BRCA1 families) but who would nevertheless benefit from breast
cancer screening at an earlier age owing to an increased risk for
early-onset breast cancer.
Breast cancer risk is determined by genetic factors and non-
genetic factors, for example, reproductive factors (Beral and
Reeves, 1993; Kelsey et al, 1993). An increased age at first full-term
pregnancy and low parity have been associated with an increased
risk of developing breast cancer in the developed world (Kelsey
et al, 1993). In the short term, a first full-term pregnancy increases
the risk of breast cancer (Beral and Reeves, 1993). Each subsequent
live-birth reportedly decreases the risk of breast cancer by 30%
and after three full-term pregnancies, the short-term risk of
developing breast cancer is similar to the risk of nulliparous
women (McCredie et al, 1998). In the long-term, a full-term
pregnancy confers a decreased risk of developing breast cancer
(McCredie et al, 1998) and each subsequent full-term pregnancy
magnifies this protective effect.
In the developing world, a higher proportion of the diagnosed
breast cancers are early-onset breast cancers Parkin et al (2002)
compared to the developed world. This fact is unexpected, as
multiple pregnancies and young age at first full-term pregnancy
are much more common in the developing world than in the
developed world. Therefore, the higher proportion of early-onset
breast cancer may be owing to either genetic or non-genetic factors
aside from reproductive factors. That genetic factors play an
important role is suggested by studies, which show that early-onset
breast cancer is more common in African-American women than
in white women in the US (Amend et al, 2006; Ries et al, 2006) and
that multiparity is associated with an increased breast cancer risk
before age 45 years in young African-American women (Palmer
et al, 2003), but not in young white women (Hall et al, 2005).
Insulin-like growth factor-1 (IGF-1) levels are higher in young
black woman than in young white women (Jernstro ¨m et al, 2001a)
and a higher level of circulating IGF-1 is a known risk factor for
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searly-onset breast cancer (Peyrat et al, 1993; Hankinson et al, 1998;
Renehan et al, 2004; Sugumar et al, 2004; Fletcher et al, 2005;
Schernhammer et al, 2005). It has been estimated that between 38
and 77% of the individual variation in IGF-1 levels is because of
genetic factors (Harrela et al, 1996; Verhaeghe et al, 1996).
Circulating IGF-1 levels may be modified (Rosen et al, 1998) by a
cytosine-adenine (CA) repeat in the proximity of the promoter,
1kb upstream from the transcription start site of the IGF1 gene
(Rotwein et al, 1986). The 19-repeat allele is the most common CA
repeat length among white women and only 6–13% of white
women have no 19-repeat allele (IGF1-19/-19 genotype) (Jernstro ¨m
et al, 2001a,b, 2005; Vaessen et al, 2001; DeLellis et al, 2003),
whereas more than 32% of black women and men have the
IGF1-19/-19 genotype (Jernstro ¨m et al, 2001a; Schildkraut et al,
2005). The IGF1-19/-19 genotype is thus approximately three times
more common in black women than in white women. Further-
more, the IGF1-19/-19 genotype is present in 16% of Indian-
Pakistani women and in over 33% of other Asian women
(Jernstro ¨m et al, 2001a; Wen et al, 2005).
Breast cancer risk appears to be influenced by the inter-
action between the IGF1 genotype and non-genetic factors.
Oral contraceptive (OC) use in combination with the IGF-19/-19
genotype increases the risk of early-onset breast cancer (Jernstro ¨m
et al, 2005; Cleveland et al, 2006). In women who never had
used OCs, the IGF1-19/-19 genotype was associated with a
decreased risk of early-onset breast cancer as compared
with women who have at least one copy of the 19-repeat
allele (IGF1þ19) (Cleveland et al, 2006). Oral contraceptive use
decreased IGF-1 levels in women with the IGF1þ19 genotype
but increased IGF-1 levels in white, black, Asian and Indian-
Pakistani women with the IGF-19/-19 genotype (Jernstro ¨m et al,
2001a). The effects of hormone replacement therapy (HRT),
alcohol intake, body mass index (BMI) and smoking on
breast cancer risk were all likewise modified by the presence or
absence of the IGF-19/-19 genotype (Cleveland et al, 2006). The
interaction between multiparity and the IGF1-19/-19 genotype on
breast cancer risk was not addressed in the study by Cleveland
et al, 2006.
The protective effect of increasing parity on breast cancer risk in
the developed world is thought to be mediated in part by decreasing
circulating IGF-1 levels (Holmes et al, 2002). As multiparity is
protective against breast cancer in the developed world but not in
the developing world, as the IGF1-19/-19 genotype is more common
among black, Indian-Pakistani and other Asian women than among
white women, and as the IGF1-19/-19 genotype inverts the effect of
several non-genetic factors on breast cancer risk, we aimed to
investigate whether the effect of multiparity on age at breast cancer
diagnosis is influenced by the IGF1-19/-19 genotype.
MATERIALS AND METHODS
All women with a primary breast cancer were invited to take
part in an ongoing study of breast cancer at the Lund University
Hospital, Sweden, regardless of ethnic background, age and
stage. Patients who had recently been diagnosed and treated for
another type of cancer were not eligible to participate. Four
hundred and three patients were included between October 2002
and July 2006. The study was approved by the Ethics Committee of
the Lund University. All patients provided a written informed
consent.
During the pre-operative visit to the Department of Surgery of
the Lund University Hospital, a research nurse collected blood
samples (EDTA plasma and serum) and recorded the time and date
when the blood samples were drawn. The blood was centrifuged
and separated. Serum, EDTA plasma and blood cells were stored at
 701C. All samples were labelled with serial codes to enable
blinded analyses.
Body weight, height, waist and hip circumferences and breast
volumes were measured. The breast volume was measured with
plastic cups used by plastic surgeons doing breast reductions. They
come in the following 11 sizes: 200, 275, 350, 500, 650, 800, 950,
1150, 1325, 1500 and 2000ml (Ringberg et al, 2006).
All patients filled out a baseline questionnaire including
questions on the use of exogenous hormones and concomitant
medications, smoking, alcohol intake, reproductive history and
family history of cancer.
Patients who had not experienced a menstrual period during the
last year were defined as postmenopausal. However, postmeno-
pausal patients who used HRT may have had HRT induced
bleeding and may therefore have been misclassified as premeno-
pausal. Patients who had had their uterus removed before
menopause but not their ovaries may also have been misclassified
as postmenopausal. We therefore classified patients according to
age (o 50 years or X50 years of age) instead of reported
menopausal status. We chose the cutoff at age 50 years as others
have shown that high IGF-1 levels influence the risk of breast
cancer in women under the age of 50 years (Hankinson et al, 1998).
We also chose to use a cutoff age of 45 years as Lund’s screening
program for breast cancer starts at this age.
Additional baseline information including type of surgery,
sentinel node biopsy, axillary node dissection, tumour size,
histological type and grade, axillary node involvement, signs of
distant metastases, oestrogen receptor and progesterone receptor
status was obtained from each patient’s chart and pathology
report. Oestrogen receptor status and progesterone receptor status
were reported as either positive or negative. HER-2/neu status was
not routinely analysed.
Genetic analysis
Genomic DNA was extracted from 300ml of peripheral blood using
Wizard, Genomic DNA Purification Kit (Promega, Madison, WI,
USA). The CA repeat in the proximity of the IGF1 promoter ranged
in size from 11 to 23 repeats. Polymerase chain reaction (PCR)
primers 50-GCTAGCCAGCTGGTGTTATT and 50-GTTTCTTAC
CACTCTGGGAGAAGGGTA were used, where the forward primer
was fluorescently labelled with FAM (MWG-Biotech AG, Ebers-
berg, Germany). Polymerase chain reaction was performed in 15ml
reactions using 25ng of DNA, 0.4mM of each primer, 0.1mM of each
deoxynucleotide (Amersham Biosciences, Buckinghamshire, UK),
5% DMSO (Sigma, St Louis, MO, USA), 2.5mMMgCl2 (Applied
Biosystems, Foster City, CA, USA), 1 PCR Gold Buffer (Applied
Biosystems, Foster City, CA, USA) and 1U AmpliTaq Gold
(Applied Biosystems, Foster City, CA, USA).
The PCR product was analysed in an ABI3100 Prism
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA)
and the results were evaluated using Genescan software.
The number of repeats was determined by sequencing samples
of varying sizes (Big Dye, Terminator Cycle Sequencing,
Applied Biosystems, Foster City, CA, USA) and using them as
standards in the fragment analysis. The results from the ABI3100
Prism Genetic Analyzer were manually evaluated and each sample
was read in duplicate. The first 360 samples were analysed using
this method.
For quality control, the first 352 samples were run in duplicate
in separate PCR and fragment analyses. Thereafter, every fourth
sample was run in duplicate. The concordance rate was 98.3%. The
discordant samples were re-checked, and we found that the
genotypes were identical in the separate PCR and fragment
analyses, but that the wrong peaks had been manually selected
during one of the readings.
In April 2006, the system was upgraded to an ABI Prism
3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). Forty-three samples were run on the upgraded system.
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sThe repeat lengths were manually evaluated, as stated above, as
well as automatically evaluated by the GeneMapper Software v.4.0.
The concordance rate was 100% between the manual and
automatic readings. The GeneMapper software could not deter-
mine repeat sizes below 17 repeats, but these alleles are rare
(0.2%).
Statistical analysis
Data analysis was performed with the statistical software SPSS 13.0.
for Windows (SPSS Inc. Chicago, IL, USA). For univariate analyses,
w
2 square analysis was used for dichotomous variables and
Student’s t-test was used for continuous variables. Age at diagnosis
was used as a continuous variable. Age at diagnosis was also
categorised as age o 50 years (yes/no) and age o 45 years (yes/
no). Multiparity was classified as having two or more children
(yes/no). The IGF1-19/-19 genotype was classified as having no
IGF1 19-repeat allele (yes/no). Multivariate linear regression was
used to examine the relationship between the IGF1-19/-19 genotype
and multiparity on age at breast cancer diagnosis. An interaction
variable was computed between these two factors. Adjustments
were carried out for other factors such as OC use, HRT use, alcohol
intake, BMI and current smoking. The study was based on an a
priori hypothesis, namely, that the IGF1 genotype in combination
with multiparity, is associated with early-onset breast cancer.
Therefore no adjustment for multiple testing is required for the
P-value for interaction, neither in the univariate nor in the
multivariate analyses. All P-values are two-tailed and presented
without Bonferroni correction for multiple testing.
RESULTS
Age at diagnosis and parity
The baseline characteristics for all patients (n¼403) are shown in
Table 1. Age at breast cancer diagnosis ranged from 25 to 99 years,
with a mean age of 58.5 years. We classified patients diagnosed
o 50 years of age as younger patients (n¼96) and patients
diagnosed X50 years of age as older patients (n¼307). One
hundred and twenty-eight patients were nulliparous or uniparous
whereas 275 patients were multiparous, that is, had two or more
children. Parity did not differ between the younger and the older
patients (1.8 children vs 1.9 children; P¼0.49), but age at first full-
term pregnancy was higher in the younger than in the older
patients (26.6 vs 24.6 years; P¼0.001, significant also after
Bonferroni correction). The only factor included in Table 1 that
was associated with the IGF1-19/-19 genotype was age at breast
cancer diagnosis. Patients with the IGF1-19/-19 genotype had a 3.5-
year earlier age at diagnosis compared with patients with the
IGF1þ19 genotype, (P¼0.04).
IGF1-19/-19 genotype frequency and age at diagnosis
The allele frequency distribution of the IGF1 CA-repeat length in
all patients is described in Table 2. Overall, 12.9% carried the
IGF1-19/-19 genotype. The distribution was not equal in all age
groups. The IGF1-19/-19 genotype was most common (over 20%)
in patients diagnosed before age 45 years and in patients diagnosed
between the ages of 55 and 59 years, and thus displayed a biphasic
pattern, (Figure 1). Age did not differ between patients who were
Table 1 Baseline characteristics of all patients, patients younger than 50 years and patients aged 50 years or older
All patients (n¼403)
Mean (7s.d.) or percent n
Age at diagnosis o 50 years (n¼96)
Mean (7s.d.) or percent n
Age at diagnosis X50 years (n¼307)
Mean (7s.d.) or percent n
Age at
diagnosis
(years)
58.5 (11.5) 403/403 43.4 (5.2) 96/96 63.2 (8.4) 307/307
Age at
menarche
(years)
13.25 (1.3) 399/403 12.9 (1.2) 94/96 13.4 (1.3) 305/307
Pre-
menopausal
(%)
25 402/403 75 96/96 9 306/307
Age at
menopause
(years)
49.1 (5.1) 290/403 39.7 (5.8) 17/96 49.7 (4.4) 273/307
Pregnancies 2.3 (1.4) 403/403 2.5 (1.4) 96/96 2.2 (1.4) 307/307
Parity 1.9 (1.2) 403/403 1.8 (1.0) 96/96 1.9 (1.2) 307/307
Age at first full-
term
pregnancy, in
parous women
25.1 (4.9) 334/403 26.6 (4.3) 82/96 24.6 (4.9) 252/307
OC 69 403/403 91 96/96 62 307/307
HRT, ever 45 403/403 11 96/96 56 307/307
Current
smoker, yes
22 403/403 18 96/96 23 307/307
Current
teetotaller, yes
11 403/403 13 96/96 11 307/307
1 and/or 21
relative with
breast cancer
34 388/403 37 92/96 33 296/307
BMI (kg/m
2) 25.3 (4.4) 401/403 24.3 (4.4) 96/96 25.6 (4.3) 305/307
Waist to hip
ratio
0.84 (0.08) 399/403 0.82 (0.08) 94/96 0.84 (0.08) 305/307
Total breast
volume (cm
3)
1156 (682) 394/403 985 (574) 93/96 1208 (705) 301/307
Abbreviations: BMI, body mass index; HRT, hormone replacement therapy; OC, oral contraceptives.
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sheterozygous and patients who were homozygous for the 19-repeat
allele (59.0 vs 58.8 years; P¼0.86). We therefore combined these
two groups and classified their genotypes as IGF1þ19.
The frequency of IGF1-19/-19 genotype in relation to parity
and age at diagnosis
Younger patients with the IGF1-19/-19 genotype had more children
than younger patients with the IGF1þ19 genotype (2.4 children vs
1.7 children; P¼0.01). In fact, only one young patient with the
IGF1-19/-19 genotype had less than two children, that is, one child.
Parity did not differ by IGF1-19/-19 genotype among the older
patients (1.9 children vs 1.9 children; P¼0.85).
Among the younger multiparous patients, 19.7% carried the
IGF1-19/-19 genotype compared with 11.6% among all other
patients, odds ratio (OR) 1.7 (95% confidence interval (CI) 0.96–
3.0; P¼0.07). As mammography is initiated at age 45 years in
Lund, Sweden, we reanalysed our results using 45 years as an age
cutoff. With this age cutoff, the IGF1-19/-19 genotype was more
than twice as common in multiparous patients diagnosed before
age 45 than in other patients (27.3% vs 11.6%), OR 2.3 (95% CI
1.3–4.4; P¼0.01).
The effect of IGF1-19/-19 genotype and parity on age at
diagnosis
In multiparous patients with the IGF1-19/-19 genotype, the mean
age at breast cancer diagnosis was 9.2 years earlier compared with
uniparous or nulliparous patients (P¼0.006). Age at breast cancer
diagnosis was not significantly influenced by multiparity in women
with the IGF1þ19 genotype (P¼0.33). The interaction between
multiparity and the IGF1-19/-19 genotype on age at breast cancer
diagnosis, which was our a priori hypothesis, was highly
significant (P¼0.007) (Table 3), and it remained significant after
adjustment for ever OC use, ever HRT use, alcohol intake, BMI and
current smoking (Pinteraction¼0.03).
Nine patients had twins. Five of these nine patients had only one
full-term pregnancy. The results remained essentially unchanged
when these patients were reclassified as uniparous instead of
multiparous. We then analysed the effect of recognised pregnan-
cies (whether full-term or not). The interaction between two or
more recognised pregnancies and the IGF1-19/-19 genotype on the
age at breast cancer diagnosis was still significant (P¼0.02). The
one uniparous patient with the IGF1-19/-19 genotype whose breast
cancer was diagnosed before age 50 years had in fact had several
recognised pregnancies; no patient with the IGF1-19/-19 genotype
with less than two recognised pregnancies was diagnosed before
age 57 years.
IGF1 genotype and mode of cancer detection, tumour
characteristics and family history of breast cancer
Among the 322 patients aged 45–74 years, there was no difference
in mode of detection in patients with or without the IGF1-19/-19
genotype (P¼0.82). IGF1 genotype was associated with neither of
the following tumour characteristics: tumour size, nodal involve-
ment, grade, oestrogen receptor status or progesterone receptor
status in either age group (all P values X0.16) nor with a history of
breast cancer in a first and/or second degree relative (P¼0.70).
DISCUSSION
The main finding of this study was that there was a highly
significant interaction between multiparity and the IGF1-19/-19
genotype on age at breast cancer diagnosis. Multiparous patients
with the IGF1-19/-19 genotype had a 9.2-year earlier age at breast
cancer diagnosis compared with nulliparous or uniparous patients
with the same genotype. Among our study population, no patient
with the IGF1-19/-19 genotype and less than two recognised
pregnancies (whether full-term or not) was diagnosed before age
57 years. Among women with the IGF1þ19 genotype, multiparity
had no significant effect on age at diagnosis. The interaction
between the IGF1-19/-19 genotype and multiparity on the age at
Table 2 The allele frequencies of the IGF1 CA-repeat allele in all
patients. The percentage does not add up to 100%, because it was rounded
off
All women (n¼403)
[CA]n No. of alleles %
11 1 (0.1)
12 —
13 —
14 —
15 1 (0.1)
16 —
17 21 (2.6)
18 31 (3.8)
19 525 (65.1)
20 167 (20.7)
21 46 (5.7)
22 12 (1.5)
23 2 (0.2)
n¼806
Abbreviations: CA, cytosine-adenine; IGF, insulin-like growth factor. This is the most
common repeat length. The common 19 repeat allele is bolded.
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Figure 1 Frequency of the IGF1-19/-19 genotype in the 403 patients
according to age at diagnosis. The total number of women in each age
category is indicated. The IGF1-19/-19 genotype was most common (over
20 %) in patients diagnosed before age 45 years and in patients diagnosed
between the ages of 55 and 59 years and thus displayed a biphasic
distribution.
Table 3 Age (mean,7s.d.) at breast cancer diagnosis in relation to
multiparity and IGF1 genotype
Age at breast cancer diagnosis
IGF1+19 IGF1-19/-19
0–1 children 58.0 (712.1) 62.3 (710.9) P¼0.23
n¼115 n¼13
2+ children 59.3 (711.3) 53.1 (79.5) P¼0.001
n¼236 n¼39
P¼0.33 P¼0.006 Pinteraction¼0.007
Abbreviations: CA, cytosine-adenine; IGF, insulin-like growth factor. There was a
significant interaction on age at breast cancer diagnosis in multiparous patients and in
patients having less then two children depending on the presence (IGF1+19)o r
absence (IGF1-19/-19) of the IGF1 19 CA-repeat allele
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sbreast cancer diagnosis has to our knowledge not been reported
previously.
We also found that the IGF1-19/-19 genotype was more than
twice as common among the youngest patients (diagnosed o45
years of age) who were multiparous compared with all other
patients. It was noteworthy that only one of the young breast
cancer patients with the IGF1-19/-19 genotype had less than two
children. This observation strengthens the hypothesis that it is the
combination of the IGF1-19/-19 genotype and multiparity that is
deleterious and suggests that the IGF1-19/-19 genotype may be
associated with a substantial number of the early-onset breast
cancers in the developing world where both this genotype and
multiparity are common. Conversely, in China, where it is
uncommon to have more than one child, the IGF1-19/-19 genotype
was associated with a decreased risk of early onset breast cancer
(Wen et al, 2005). Their result is in line with our finding that
patients with the IGF1-19/-19 genotype and fewer than two
pregnancies had a later age at diagnosis.
As suggested by Holmes et al (2002) parity may exert its
protective effect by lowering IGF-1 levels post-partum. Such results
were not replicated in a previous study of young white women
from high-risk breast cancer families (Jernstro ¨m et al, 2005). In
that study, the IGF-1 levels of parous and nulliparous women were
similar. Furthermore, we found that the frequency of the IGF1-19/-19
genotype was significantly higher among known BRCA1 carriers
compared with other high-risk women and we have reported
previously that each pregnancy up to three confers an increased
risk for breast cancer before age 40 years among BRCA1 and
BRCA2 carriers (Jernstro ¨m et al, 1999). We therefore hypothesise
that the IGF-1 levels do not decrease post-partum in women with
the IGF1-19/-19 genotype. Each pregnancy may thus confer an
increased risk of early-onset breast cancer.
In our study, patients with the IGF1-19/-19 genotype who had
two or more children had a lower age at diagnosis. In the study by
Cleveland et al (2006), the IGF1-19/-19 genotype modified the
breast cancer risk after exposure to hormonal factors such as OCs
and women with the IGF1-19/-19 genotype who had ever used OCs
had an increased breast cancer risk whereas this genotype was
protective in women without OC exposure. However, our results
remained significant after adjustment for OC use, HRT use as well
as alcohol intake, BMI and current smoking.
The frequency of the IGF1-19/-19 genotype was 12.9% in our
patient population and is consistent with the frequency among
white women that has been reported to vary between 6 and 13%
(Vaessen et al, 2001; Jernstro ¨m et al, 2001b, 2005; DeLellis et al,
2003). In this study, we observed a biphasic variation in the
frequency of the IGF1-19/-19 genotype in relation to age at
diagnosis. This observation needs confirmation in other studies, as
it has not been previously reported. Among multiparous patients
diagnosed before age 50 years, the frequency of the IGF1-19/-19
genotype was almost twice as common as in the other patients. As
mammography screening is initiated at the age of 45 years in Lund,
Sweden, we then re-analysed our results. The frequency of the
IGF1-19/-19 genotype in the multiparous patients (o 45 years) was
then more than twice as common as in the other patients. As
examining the frequency of the IGF1-19/-19 genotype in relation to
different age cutoffs was not part of our a priori hypothesis, these
results have to be regarded as hypothesis generating. However,
they suggest that multiparous patients with the IGF1-19/-19 may
not only have an earlier age at breast cancer diagnosis but also an
increased risk of developing the malignancy.
This study was based on a series of breast cancer patients
diagnosed with a primary breast cancer at Lund University
Hospital, Sweden. All breast cancers were verified by the
Department of Pathology, Lund University Hospital. The baseline
information was filled out by all patients at the pre-surgical visit,
which minimises bias owing to survival differences between
patients.
It has been suggested that contradictory findings regarding IGF1
CA-repeat lengths and breast cancer risk may be owing to
differences in the methods used to determine the repeat lengths,
sequencing or fragment analysis (Tran et al, 2004). The repeat
numbers obtained with fragment analysis have differed when
analysing the results on an ABI Prism 3100 Genetic Analyzer using
the internal standard supplied by the manufacturer as compared to
the results received when using a ladder that has been verified by
direct sequencing (Rodriguez et al, 2006). It is therefore important
to emphasise that all the genetic analyses in this study were
performed with the same method, that is, fragment analysis on an
ABI Prism 3100 or a 3130xl Genetic Analyzer, using control
samples with lengths verified by direct sequencing. To evaluate the
reproducibility of this method, 353 results were re-run and the
concordance rate was 98.3%. When re-examining the discordant
samples, we found that the errors were of human nature in
misinterpreting the technically sound genotype results. This will
not be an issue in the future when the samples will also be
automatically evaluated by the GeneMapper software.
The IGF1 genotype was not associated with TNM staging, grade
or hormone receptor status in either age group, nor was it
associated with mode of detection among the patients whose
cancer was diagnosed between the ages of 45 and 74 years. As
early-onset breast cancer in itself is associated with a poorer
prognosis (Sidoni et al, 2003), it may be advantageous to initiate
breast cancer screening among multiparous women with the
IGF1-19/-19 genotype at an earlier age. Alternative screening
methods may be needed in this age group as mammography shows
poor sensitivity in young women (Houssami et al, 2003).
Conversely, among patients with fewer than two children, the
IGF1-19/-19 genotype was associated with a later age of breast
cancer onset, and these women may initiate screening at a later
age. If confirmed, our data suggest that IGF1 genotyping should be
considered in all women with multiple pregnancies to determine
the optimal start age for breast cancer screening.
CONCLUSION
Our findings suggest that the combination of IGF1-19/-19 genotype
and multiparity is associated with an early age at breast cancer
diagnosis. These findings may explain why the proportion of early-
onset breast cancers is higher in the developing than in the
developed world. Further studies are warranted to confirm our
findings. If confirmed, the IGF1-19/-19 genotype may help identify
a subgroup of patients for whom early breast cancer screening is
warranted as well as a subgroup of patients for whom the onset of
regular screening can safely be postponed.
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